Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.

Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.